Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
This application is continuation of U.S. Application No. 17/258,273, which is a national stage filing under section 371 of International Application No. PCT/GB2019/051903, filed on July 5, 2019, and published on January 9, 2020 as WO 2020/008206 A1, which claims priority to Great Britain Application No. 1811165.8, filed on July 6, 2018.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on Sept. 20, 2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Claim Status
Claims 1-20 are currently pending and subject to examination.
Claim Rejections – 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
“(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.”
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
“The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.”
Claim 17-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 17 is indefinite because it recites a compound of formula NHR3R4 but claim 1 is a single species with no R-groups and claim 17 does not define this group. The drawn structure appears to refer to this structure, but it is unclear. Appropriate correction is required.
Claim 18 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: the steps of removing a protecting group on an intermediate compound and the steps of forming a pharmaceutically acceptable salt of the compound of formula (I).
One of ordinary skill in the art cannot determine the metes and bounds of claim 18 because it is unclear what is “an intermediate compound.” Claim 18 recites “removal of a protecting group on an intermediate compound to prepare the compound of formula (I).” It is unclear what compounds and what steps are involved in this process. Neither reactant in the steps has a protecting group. Direct coupling of the two gives unprotected formula (I). The Specification describes these steps as alternatives, not as a sequence (¶¶ [0137]-[0142] of the published specification). Claim 18 purports to require deprotection in addition to step (a), which as claimed, already prepares a compound of formula (I). Here, a person of ordinary skill in the art could not determine the identity of the intermediate compound, at what point in the claimed process it is formed or deprotected, and whether claim 18 requires a protected reactant in step (a) that claim 17 does not recite, or a second separate route to formula (I).
Claim 18 additionally recites “formation of a pharmaceutically acceptable salt of the compound of formula (I), but it is unclear what steps are involved how the pharmaceutically acceptable salt is formed. For example, does it involve reacting the compound of formula (I) with a salt or is the salt formed at an intermediate step in the synthesis method?
Claims 19-20 recite the process according to claim 17, for preparing the compound of formula (I) (19) or for preparing the pharmaceutically acceptable salt of the compound of formula (I). It is unclear how the steps of claim 17 are further limited if a compound or a salt of the compound is prepared. Therefore, one of ordinary skill in the art cannot determine the metes and bounds of the claims.
Nonstatutory Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-23 of U.S. Patent No. 12,128,028 B2 (herein “the ‘028” patent). Although the claims at issue are not identical, they are not patentably distinct from each other because the ‘028 patent claims the compound of formula (I) of instant claim 1, or a pharmaceutically acceptable salt or solvate therefore (genus claims 1-17, species claim 18), pharmaceutical compositions thereof (claims 19-20), the same claimed methods of treatment (claim 21), and the same synthesis method (claims 23-24). Example 48, claimed in claim 18 of the ‘028 patent, is the claimed compound of formula (I).
Examiner’s Suggestion
The Examiner suggests amending claims 13-16 to recite “in need thereof” following “a subject.” The “wherein clause” only narrows the preamble but this type of preamble is normally not further limiting without “in need thereof” following “subject.” The clause would be meaningless unless the preamble limits the claim, which suggests the Applicant relies on it to define the invention.
Conclusion
No claim is found to be allowable.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to HEATHER DAHLIN whose telephone number is (571)270-0436. The examiner can normally be reached 9-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached on (571) 272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 86-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/HEATHER DAHLIN/Examiner, Art Unit 1629
/JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629